RxDoctor Payments Data

Edward Kaplan, MD

Hematology & Oncology · Morton Grove, ILNPI 1639181084

Payments from drug & device makers

$126,404in general payments, 2019–2025

Across 1,279 payments — averaging $98.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Helsinn Healthcare SA$21K
  • Macrogenics, Inc.$16K
  • GSK$15K
  • Amgen$15K
  • Johnson & Johnson$13K
  • AstraZeneca$10K
  • plus $37K from 54 others

What the payments were for

  • Consulting fees$27,19046%
  • Speaking & faculty fees$2,1804%
  • Travel & lodging$2,7225%
  • Food & beverage$24,28641%
  • Education$1,0842%
  • Other$1,1822%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Helsinn Healthcare SA5$20,828
Macrogenics, Inc.3$15,785
GSK16$14,973
Amgen42$14,553
Johnson & Johnson(2 entities)91$13,390
AstraZeneca(2 entities)79$9,532
Eisai Inc.19$5,953
Novartis152$3,357
Puma Biotechnology, Inc.6$2,796
Athenex Pharmaceutical Division, LLC2$2,150
Novocure Inc.5$2,110
Pharmacyclics LLC, An Abbvie Company20$2,023
Daiichi Sankyo Inc.42$1,564
Pfizer71$1,258
Merck57$1,253
E.r. Squibb & Sons, L.L.C.56$1,010
Incyte Corporation38$933
Lilly USA, LLC35$895
Bristol Myers Squibb43$817
Takeda Pharmaceuticals U.S.A., Inc.43$816
Janssen Scientific Affairs, LLC1$758
Sanofi29$725
Genentech USA, Inc.56$715
Seagen Inc.26$646
Dendreon Pharmaceuticals LLC26$545
EMD Serono, Inc.23$487
AbbVie31$480
Astellas Pharma US Inc15$380
Regeneron Healthcare Solutions, Inc.14$346
Beigene USA, Inc.12$330
Gilead(2 entities)15$322
Tersera Therapeutics LLC17$303
Jazz Pharmaceuticals Inc.11$275
Adaptive Biotechnologies Corporation9$267
Menarini Silicon Biosystems, Inc.8$240
Bayer10$232
Servier Pharmaceuticals LLC10$219
Exelixis Inc.10$198
Agios Pharmaceuticals, Inc.6$169
Pharmacosmos Therapeutics Inc.7$167
Blue Earth Diagnostics7$158
Array Biopharma Inc8$147
Blueprint Medicines Corporation5$140
Morphosys, US Inc.6$129
Sobi, Inc5$123
Karyopharm Therapeutics Inc.4$114
Alnylam Pharmaceuticals Inc.5$109
Springworks Therapeutics, Inc.4$103
Deciphera Pharmaceuticals Inc.4$95
Mirati Therapeutics, Inc.3$83
Spectrum Pharmaceuticals Inc.4$76
AVEO Pharmaceuticals, Inc.3$74
Sumitomo Pharma America, Inc.3$65
Foundation Medicine, Inc.3$63
Rigel Pharmaceuticals, Inc.3$62
Pharmaessentia USA Corporation2$53
G1 Therapeutics, Inc.3$51
ADC Therapeutics America, Inc.2$50
Legend Biotech USA Inc.2$48
CTI Biopharma Corp.2$48

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$126,404 in reported general payments places this provider in the 70th percentile of 580 hematology & oncology providers in Illinois.

See all hematology & oncology providers in Illinois

Medicare billing

Part B allowed, 2024
$4,078,139
Medicare patients
665
Services billed
138,139

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PomalystPomalidomide23$513,424
ImbruvicaIbrutinib33$500,175
TagrissoOsimertinib Mesylate18$303,076
CalquenceAcalabrutinib Maleate23$270,192
InlytaAxitinib11$227,154
VerzenioAbemaciclib11$165,909
LonsurfTrifluridine/Tipiracil Hcl16$163,965
CreonLipase/Protease/Amylase17$17,740
EliquisApixaban19$11,668
Imatinib Mesylate15$1,965
Exemestane14$1,590
ValacyclovirValacyclovir Hcl20$1,536
Letrozole94$1,212
Dexamethasone28$692
Prochlorperazine Maleate34$536

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaTagrisso, Calquence$9,532$573,26841 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$1,010$513,42423 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$2,023$500,17533 claims
PfizerInlyta, Eliquis$1,258$238,82330 claims
Lilly USA, LLCVerzenio$895$165,90911 claims
AbbVieCreon$480$17,74017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 580 hematology & oncology providers in Illinois.

Other hematology & oncology in Morton Grove

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →